DermTech Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Bret Christensen
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | n/a |
| Management average tenure | 1.8yrs |
| Board average tenure | 2.5yrs |
Recent management updates
Recent updates
We're A Little Worried About DermTech's (NASDAQ:DMTK) Cash Burn Rate
Mar 02
Investors Don't See Light At End Of DermTech, Inc.'s (NASDAQ:DMTK) Tunnel And Push Stock Down 28%
Mar 02Revenues Working Against DermTech, Inc.'s (NASDAQ:DMTK) Share Price
Dec 28Companies Like DermTech (NASDAQ:DMTK) Could Be Quite Risky
Sep 18Can DermTech (NASDAQ:DMTK) Afford To Invest In Growth?
Jun 14Need To Know: The Consensus Just Cut Its DermTech, Inc. (NASDAQ:DMTK) Estimates For 2023
May 10DermTech, Inc. (NASDAQ:DMTK) Not Doing Enough For Some Investors As Its Shares Slump 37%
May 06We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate
Jan 16Analyst Forecasts Just Became More Bearish On DermTech, Inc. (NASDAQ:DMTK)
Nov 08Will DermTech (NASDAQ:DMTK) Spend Its Cash Wisely?
Oct 11DermTech grants stock options
Oct 11Diving Into DermTech
Sep 01Earnings Release: Here's Why Analysts Cut Their DermTech, Inc. (NASDAQ:DMTK) Price Target To US$23.80
Aug 10DermTech: Approaching An All Or Nothing Moment
Jun 13We're Keeping An Eye On DermTech's (NASDAQ:DMTK) Cash Burn Rate
Jun 04DermTech - Taking A Second Look At The Growth Thesis
Mar 31DermTech: Adoption Headwinds And Earnings Misses
Dec 23Companies Like DermTech (NASDAQ:DMTK) Are In A Position To Invest In Growth
Dec 02DermTech - Game Changer, Set To Become The Leader In Skin Diagnostics
Sep 15We Think DermTech (NASDAQ:DMTK) Can Afford To Drive Business Growth
Sep 03DermTech: Transforming The Melanoma Diagnosis Landscape
Aug 31DermTech: Becoming More Appealing, Despite Nosebleed Valuation
Aug 09DermTech appoints former Myriad Genetics executive as new chief medical officer
Jun 16We're Not Very Worried About DermTech's (NASDAQ:DMTK) Cash Burn Rate
Jun 05DermTech initiated buy at BTIG on the potential of PLA test
May 03DermTech rises 18% on report Cigna covering early melanoma detection test
Apr 27CEO
Bret Christensen (52 yo)
less than a year
Tenure
Mr. Bret Christensen serves as Chief Executive Officer, President and Director at DermTech, Inc. since May 2023. He serves as Director of Axena Health, Inc. Mr. Christensen had been Chief Commercial Office...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CFO, Treasurer & Secretary | 4.6yrs | US$1.46m | 0.79% $ 169.2k | |
| General Counsel | 3.3yrs | US$1.20m | 0.17% $ 35.4k | |
| President | less than a year | no data | no data | |
| Chief Information Officer | 1.5yrs | no data | no data | |
| Senior Director of Investor Relations | no data | no data | no data | |
| Chief Compliance Officer | 1.8yrs | no data | no data | |
| Chief Medical Affairs Officer | 7.3yrs | US$480.83k | no data | |
| Chief Medical Officer | 2.8yrs | no data | no data | |
| Senior Vice President of Research & Development | 1.8yrs | no data | no data | |
| Chief Commercial Officer | less than a year | no data | no data |
1.8yrs
Average Tenure
53yo
Average Age
Experienced Management: DMTK's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | less than a year | no data | no data | |
| Independent Director | 4.7yrs | US$239.85k | 0.29% $ 60.9k | |
| Independent Director | 1.8yrs | US$312.01k | 0.013% $ 2.7k | |
| Independent Chairman of the Board | 7.8yrs | US$272.18k | 0.35% $ 75.5k | |
| Independent Director | 1.8yrs | US$312.43k | 0.057% $ 12.2k | |
| Independent Director | 4.7yrs | US$240.18k | 0.20% $ 42.6k | |
| Independent Director | 2.5yrs | US$217.05k | 0.089% $ 19.1k |
2.5yrs
Average Tenure
56yo
Average Age
Experienced Board: DMTK's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.